Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder

BACKGROUND: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with long...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Psychopharmacol Bull
Main Authors: Josiassen, Richard C., Kane, John M., Liang, Grace S., Burke, Joshua, O’Brien, Christopher F.
Formato: Artigo
Idioma:Inglês
Publicado em: MedWorks Media Global 2017
Assuntos:
Original Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546552/
https://ncbi.nlm.nih.gov/pubmed/28839341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados